Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses 1 , 2 and can function as …
from central tolerance, can generate robust immune responses 1 , 2 and can function as …
Exciting new advances in neuro‐oncology: the avenue to a cure for malignant glioma
Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for
patients with glioblastoma, the most aggressive glioma, although individually variable, has …
patients with glioblastoma, the most aggressive glioma, although individually variable, has …
[PDF][PDF] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
…, P Ivy, DT Scadden, T Benner, JS Loeffler, PY Wen… - Cancer cell, 2007 - cell.com
Using MRI techniques, we show here that normalization of tumor vessels in recurrent
glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of …
glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of …
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
[PDF][PDF] Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
PY Wen, DR Macdonald, DA Reardon… - Journal of clinical …, 2010 - neuroradiologi.dk
Currently, the most widely used criteria for assessing response to therapy in high-grade
gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or …
gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or …
Malignant gliomas in adults
Malignant gliomas, the most common type of primary brain tumor in adults, are associated
with disproportionate cancer-related morbidity and mortality. Recently, there have been …
with disproportionate cancer-related morbidity and mortality. Recently, there have been …
[PDF][PDF] Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
HS Friedman, MD Prados, PY Wen… - Journal of clinical …, 2009 - researchgate.net
… Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, WK Alfred Yung, Nina Paleologos,
Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, and …
Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, and …
[HTML][HTML] Vorasidenib in IDH1-or IDH2-mutant low-grade glioma
Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-…
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-…
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future …
PY Wen, M Weller, EQ Lee, BM Alexander… - Neuro …, 2020 - academic.oup.com
Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …
cause of morbidity and mortality. In recent years there have been important advances in …
Epidemiology of brain metastases
L Nayak, EQ Lee, PY Wen - Current oncology reports, 2012 - Springer
Brain metastases are one of the most common neurologic complications of cancer. The
incidence is 9%–17% based on various studies, although the exact incidence is thought to be …
incidence is 9%–17% based on various studies, although the exact incidence is thought to be …